Michael Zile to Comorbidity
This is a "connection" page, showing publications Michael Zile has written about Comorbidity.
Connection Strength
0.460
-
From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. Circ Res. 2021 05 14; 128(10):1451-1467.
Score: 0.135
-
Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol. 2007 Mar 06; 49(9):982-5.
Score: 0.050
-
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
Score: 0.033
-
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 12; 12(12):e006539.
Score: 0.030
-
Health-Related Quality of Life in Heart?Failure With Preserved Ejection?Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 10; 7(10):862-874.
Score: 0.030
-
Income Inequality and Outcomes in Heart?Failure: A Global Between-Country Analysis. JACC Heart Fail. 2019 04; 7(4):336-346.
Score: 0.029
-
Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019 01; 21(1):23-36.
Score: 0.028
-
Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018 03; 15(3):e1002541.
Score: 0.027
-
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016 Jul 05; 134(1):73-90.
Score: 0.024
-
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
Score: 0.023
-
Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 May; 16(5):535-42.
Score: 0.020
-
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 01; 5(5):571-8.
Score: 0.018
-
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.
Score: 0.012